oncology– tag –
-
Glioblastoma Series | Part 5: Plasticity & Escape — A Gentle Guide to OPC/AC/MES State Transitions
Plasticity & Escape — A Gentle Guide to OPC/AC/MES State Transitions Why do single agents rarely suffice? Because GBM has plasticity—it can shift among OPC-like, AC-like, and MES-like faces. Let’s build intuition and turn it into a p... -
Glioblastoma Series | Part 4: The Moving Tumor — Intuitive Guide to ECM, Adhesion, and White-Matter Tract Invasion
The Moving Tumor — Intuitive Guide to ECM, Adhesion, and White-Matter Tract Invasion Why does GBM come back even after “maximal” surgery? This beginner-first chapter explains the mobility of GBM via ECM, adhesion signaling, and the highw... -
Glioblastoma Series | Part 3: Extinguishing the Spark — Microenvironment & Immunity (MIF–CD74 Primer)
Extinguishing the Spark — Microenvironment & Immunity (MIF–CD74 Primer) This beginner-friendly chapter looks beyond the tumor mass to the “place” that makes GBM easier to grow: the microenvironment. We introduce brain immunity, ECM, ... -
Glioblastoma Series | Part 2: Where It Begins — SVZ Hypothesis and Precancerous Cells
Where It Begins — SVZ Hypothesis and Precancerous Cells (pre-CC) Beyond the tumor mass: a beginner’s map of how GBM may arise, diversify, and interact with its “niche”. Today’s Goals (3-Minute Preview) Understand what the SVZ (subventric... -
Glioblastoma Series | Part 1: Clinical Map — Symptoms, Diagnosis, Standard of Care, and the Role of TTF
A gentle, beginner-friendly walkthrough of GBM care from first symptoms to initial therapy and what to consider at recurrence—using clear, minimal jargon. Today’s Goals (3-Minute Preview) Recognize common presenting symptoms that trigger... -
Glioblastoma Series | Part 0: Primer — Brain Basics & a By-the-Numbers View of GBM
A beginner-friendly introduction: understand the brain’s building blocks and a simple, number-based overview of GBM (incidence, prognosis, and quality of life). Series Table of Contents Part 0 | GBM Primer: Brain Basics and By-the-Number... -
ecDNA in Glioblastoma: Spatial Heterogeneity and EGFRvIII Evolution (Part 2)
This Part focuses on how extrachromosomal DNA (ecDNA) shapes spatial heterogeneity and evolution in glioblastoma (GBM). We outline the extreme copy-number gains of drivers (EGFR/PDGFRA/CDK4) on ecDNA, region-to-region response gaps, and ... -
ecDNA in Cancer: Mechanisms of Diversity and Resistance (Part 1)
Extrachromosomal DNA (ecDNA) reshapes oncogene dosage, transcription, phenotypes, and spatial organization, thereby accelerating intratumor heterogeneity and therapy resistance. In Part 1, we briefly introduce non-GBM evidence up front a... -
KRAS Special Series Part 8 (Final): The Next Decade — From Cancer Control to Regeneration and Longevity
For over four decades, KRAS symbolized the “undruggable.” By the mid-2020s, it became the flagship of precision oncology. This final chapter summarizes that evolution—from structural biology to AI-driven therapeutics—and looks ahead to h... -
KRAS Special Series Part 7: The Biotech Frontline — How RAS Drug Discovery Is Being Redefined
The race to drug KRAS is reshaping not only science but the entire biotech ecosystem. Once deemed “undruggable,” KRAS became a proving ground for startups, academic spinouts, and AI-driven discovery. This part reviews key players—Revolut... -
KRAS Special Series Part 6: Beyond Resistance — Wild-Type and Mutant RAS Co-Inhibition and the Dawn of Systems RAS Therapy
The rise of KRAS inhibitors marked the end of the “undruggable” era—but tumors adapt swiftly. Resistance often stems from a cooperative reactivation between mutant and wild-type RAS. This sixth installment dissects the molecular basis of... -
KRAS Special Series Part 5: The New Wave of KRAS Drug Discovery — Degraders, RAS(ON) Inhibitors, and AI-Driven Design
KRAS has evolved from the icon of “undruggable” to the engine of next-generation oncology. Building on the success of allele-selective inhibitors (e.g., G12C), the mid-2020s ushered in three powerful paradigms: RAS(ON) inhibition, pan-KR... -
KRAS Special Series Part 4: Immunity, Aging, and Regeneration — The Future of Life Regulation Through KRAS Signaling
KRAS research has now transcended oncology. Recent studies reveal that KRAS signaling interconnects with immunity, cellular aging, and even regenerative medicine. In this fourth installment, we redefine KRAS as a “life regulator” rather ... -
KRAS Special Series Part 3: The Silent Ally — How Wild-Type KRAS Builds Resistance Networks
As KRAS-targeted therapy enters a new era, one unexpected player has captured the spotlight: Wild-type KRAS (WT-KRAS). While mutant KRAS has long been seen as the dominant oncogenic driver, emerging evidence shows that its wild-type coun... -
KRAS Special Series Part 2: What Each Allele Tells Us — Biological and Clinical Diversity of G12D, G12V, G12R, and Q61
In Part 1, we traced the long struggle to target KRAS and the breakthrough that made the “undruggable” druggable. Now we turn to a crucial question: how do different KRAS alleles shape tumor biology, signaling behavior, and clinical outc... -
KRAS Special Series Part 1: The Rise, Fall, and Rebirth of the “Undruggable” Target
Few oncogenes have shaped the landscape of cancer research as profoundly as KRAS. Since the first RAS mutation was identified in human bladder cancer cells in 1982, this small GTP-binding protein has fascinated scientists as both a myste... -
Part 2｜Inside AMPLIFY-201 Final Analysis: What the KRAS Vaccine Is Actually Moving
Takeaway: Lymph-node–targeted amphiphile delivery achieved robust dual CD4/CD8 responses. A data-driven ~9.17× immune threshold aligned with RFS/OS gains and ctDNA negativity in the adjuvant MRD setting. Contents 1. One-Minute Summary 2.... -
[2025 Oct] KRAS Cancer Vaccine Competitive Map｜Elicio, SLATE-KRAS & Academic SLP Compared (Adjuvant MRD × Off-the-Shelf Era)
Takeaway: the field is coalescing around shared neoantigens × off-the-shelf × adjuvant MRD. Elicio (ELI-002 7P) leads the pack; academic SLP + poly-ICLC programs and Gritstone’s SLATE-KRAS follow. With V941 halted, the landscape is clear... -
Oncology Drug Approval News Flash: FDA Approves Lurbinectedin Plus Atezolizumab for Maintenance in Extensive-Stage Small Cell Lung Cancer
On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) in combination with atezolizumab (Tecentriq, Genentech) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) fo... -
Series “Reading 2025 Layoffs”: Modality-by-Modality: Manufacturing, Regulatory, and Commercial Realities (Part 3)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 3 Key Takeaways The “capital-efficiency equation” is modality-specific: even with similar P2 wins, cell/gene/RNA/antibody–degrader programs require very different...
